A Phase 3 interventional study of CB-03-01 cream, 1% and Vehicle cream in Acne Vulgaris, sponsored by Cassiopea SpA. Completed at 54 sites in 3 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2020-11-20.
Sponsored by Cassiopea SpA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.
Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 3rd registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 12–55
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Allied Hospital Faisalabad · Sites in Pakistan
Ages 15+
Khyber Teaching Hospital
Ages 12–35
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Ages 12+
By country, each count listing its studies:
Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 7
First in 2012; this study’s year is marked. 3 started in 2016.
This study's enrollment of 708 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 50 across the 19 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 8 most frequent:
Cassiopea SpA is the lead sponsor of 7 studies on the registry; none are open to participants now.
Cassiopea SpA has 4 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
3 of the studies testing clascoterone in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07673094Khyber Teaching HospitalComparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris | 2027-02 |
| NCT07883538Pak Emirates Military HospitalComparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris | 2027-04-30 |
| NCT07881315Allied Hospital FaisalabadClascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing clascoterone in Acne Vulgaris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CB-03-01 cream, 1% applied twice daily for 12 weeks
Drug: CB-03-01 cream, 1%
Vehicle cream applied twice daily for 12 weeks
Drug: Vehicle cream
CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Also known as: cortexolone 17α-propionate, clascoterone (USAN, INN)
Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)
Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.
Time frame: Week 12
Change From Baseline in Non-inflammatory Lesion Counts
Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Change From Baseline in Inflammatory Lesion Counts
Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Change From Baseline in Total Lesion Counts
Absolute change from Baseline in total lesions counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Lesion Counts
Percent change from Baseline in total lesions counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-inflammatory Lesion (NIL) Counts
Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.
Time frame: Baseline and Week 12
Percent Change From Baseline in Inflammatory Lesion (IL) Counts
Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.
Time frame: Baseline and Week 12
Local Site Reactions
Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).
Time frame: Baseline, Weeks 4, 8, and 12
| Milestone | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| Started | 353 | 355 |
| Completed | 287 | 290 |
| Not completed | 66 | 65 |
| Withdrew: Lost to follow-up | 39 | 32 |
| Withdrew: Withdrawal by subject | 21 | 15 |
| Withdrew: Adverse event | 3 | 6 |
| Withdrew: Withdrawal by parent | 2 | 3 |
| Withdrew: Lack of efficacy | 0 | 3 |
| Withdrew: Noncompliance with study drug | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Multiple reasons | 0 | 2 |
Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.
| Percentage of participants | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA) | 18.4 | 9.0 |
Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.
| Non-inflammatory Lesions | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| Change From Baseline in Non-inflammatory Lesion Counts | -19.4 (-22.6 to -16.7) | -13.0 (-15.7 to -10.3) |
Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.
| Inflammatory Lesions | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| Change From Baseline in Inflammatory Lesion Counts | -19.3 (-21.1 to -17.5) | -15.5 (-17.3 to -13.6) |
Absolute change from Baseline in total lesions counts in each treatment group at Week 12.
| Total lesions | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| Change From Baseline in Total Lesion Counts | -39.1 (-43.0 to -35.1) | -28.8 (-32.6 to -24.9) |
Percent change from Baseline in total lesions counts in each treatment group at Week 12.
| percent change | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| Percent Change From Baseline in Total Lesion Counts | -37.0 (-40.9 to -33.2) | -28.4 (-32.3 to -24.6) |
Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.
| percent change | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| Percent Change From Baseline in Non-inflammatory Lesion (NIL) Counts | -30.6 (-35.6 to -25.7) | -21.6 (-26.4 to -16.8) |
Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.
| percent change | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| Percent Change From Baseline in Inflammatory Lesion (IL) Counts | -44.8 (-49.0 to -40.5) | -36.5 (-40.8 to -32.2) |
Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).
Results for this outcome have not been posted.
Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from screening visit, Baseline (Day 1) and up to Week 12/early termination.. Non-serious events are listed at a 0.6% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CB-03-01 Cream | 0/353 (0%) | 0/353 (0%) | 9/353 (2.5%) |
| Vehicle Cream | 0/355 (0%) | 1/355 (0.3%) | 18/355 (5.1%) |
| Event | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| PneumoniaInfections and infestations | 0/353 | 1/355 |
| Event | CB-03-01 Cream | Vehicle Cream |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/353 | 12/355 |
| Application painGeneral disorders | 1/353 | 3/355 |
| Application site pruritusInjury, poisoning and procedural complications | 2/353 | 3/355 |
Number of participants is based on the Intent to treat dataset.
| Age, Continuous(years) | CB-03-01 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 20.0 ± 6.7 | 19.9 ± 6.8 | 19.9 ± 6.7 |
| Sex: Female, Male(Participants) | CB-03-01 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Female | 221 | 215 | 436 |
| Male | 132 | 140 | 272 |
| Ethnicity (NIH/OMB)(Participants) | CB-03-01 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 94 | 80 | 174 |
| Not Hispanic or Latino | 259 | 275 | 534 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CB-03-01 Cream | Vehicle Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 9 | 10 | 19 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 31 | 38 | 69 |
| White | 298 | 297 | 595 |
| More than one race | 9 | 7 | 16 |
| Unknown or Not Reported | 4 | 2 | 6 |
| Baseline IGA(Participants) | CB-03-01 Cream | Vehicle Cream | Total |
|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 |
| 1 - Almost Clear | 0 | 0 | 0 |
| 2- Mild | 0 | 0 | 0 |
| 3 - Moderate | 292 | 291 | 583 |
| 4 - Severe | 61 | 64 | 125 |
| Baseline Acne Lesion Counts(Lesions) | CB-03-01 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Non-inflammatory lesions | 59.1 ± 22.2 | 60.7 ± 22.1 | 59.9 ± 22.1 |
| Inflammatory lesions | 42.4 ± 11.8 | 42.9 ± 12.3 | 42.7 ± 12.1 |
| Total Lesion Count | 101.5 ± 25.1 | 103.6 ± 26.1 | 102.6 ± 25.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in Apr 2018, 26 months.
Results were first posted in Nov 2020, 2 years 7 months after primary completion. A results delay was requested in Jun 2019.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 26 months is above that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clascoterone
Cassiopea SpA